Next Article in Journal
MicroRNAs as Molecular Targets for Cancer Therapy: On the Modulation of MicroRNA Expression
Previous Article in Journal
Dynamic Cross Talk between S1P and CXCL12 Regulates Hematopoietic Stem Cells Migration, Development and Bone Remodeling

Pharmaceuticals 2013, 6(10), 1170-1194; doi:10.3390/ph6101170

Review
Safety of Immunosuppressive Drugs Used as Maintenance Therapy in Kidney Transplantation: A Systematic Review and Meta-Analysis
Celline Cardoso Almeida 1,*, Micheline Rosa Silveira 2, Vânia Eloisa de Araújo 2, Livia Lovato Pires de Lemos 2, Juliana de Oliveira Costa 2, Carlos Augusto Lins Reis 2, Francisco de Assis Acurcio 2 and Maria das Gracas Braga Ceccato 2
1
Faculdade de Medicina, Universidade Federal de Minas Gerais, Av. Prof. Alfredo Balena, 190, Belo Horizonte/MG, Brazil
2
Faculdade de Farmácia, Universidade Federal de Minas Gerais, Av. Antônio Carlos, 6627, Campus Pampulha, Belo Horizonte/MG, Brazil; E-Mails: michelinerosa@gmail.com (M.R.S.); vaniaearaujo@gmail.com (V.E.A.); lilolemos@gmail.com (L.L.P.L.); juliana.olic@gmail.com (J.O.C.); carloslinsr@gmail.com (C.A.L.R.); fracurcio@gmail.com (F.A.A.); mgbceccato@gmail.com (M.G.B.C.)
*
Author to whom correspondence should be addressed; E-Mail: celline.cardoso@gmail.com; Tel.: +1-55-31-8861-9577.
Received: 9 July 2013; in revised form: 3 September 2013 / Accepted: 16 September 2013 /
Published: 30 September 2013

Abstract

: To evaluate the safety of regimens containing calcineurin inhibitors (CNI), proliferation signal inhibitors (TOR-I) and antimetabolites, we conducted a meta-analysis of randomized clinical trials (RCTs) and observational studies. A total of 4,960 citations were identified in our electronic search and 14 additional articles were identified through hand searching. Forty-eight articles (11,432 participants) from 42 studies (38 RCTs and four cohorts) met the inclusion criteria. Meta-analysis results revealed the following: (i) tacrolimus was associated with an increased risk for diabetes and lower risk of dyslipidemia, compared to cyclosporine; (ii) mycophenolate mofetil (MMF) was associated with increased risk for total infections, abdominal pain, diarrhea and vomiting, compared with azathioprine; (iii) sirolimus was associated with higher risk of anemia, diabetes, dyslipidemia, lymphoceles and withdrawal compared to tacrolimus or cyclosporine, and cyclosporine was associated with an increased risk of CMV infection; (iv) the combination of CNI with antimetabolites was associated with more adverse events than CNI alone; (v) TOR-I was related to more adverse events than MMF. The data observed in this meta-analysis are similar to those describe by others authors; thus, the choice of treatment must be made by the clinical staff based on specific patient characteristics.
Keywords:
kidney transplantation; immunosuppressive drugs; adverse events; meta-analysis

1. Introduction

Chronic kidney disease (CKD), most commonly defined as persistent impaired kidney function [1], is a comorbid condition with multiple manifestations that is recognized as an important worldwide public health problem. The prevalence of CKD has increased over the years. It is strongly related with ageing and is more prevalent among women [2,3,4,5] and African Americans [6].

A systematic review of population based studies [7] confirmed that impaired kidney function (iKF) is as common as diabetes mellitus in the general population, and higher quality studies have reported the prevalence of iKF to range from 1.7% in China to 8.1% in the United States. To reduce disease progression, there have been increasing efforts to promote early diagnosis of CKD [8,9]. Without proper care, CKD leads to complications of reduced kidney function, increased risk of cardiovascular disease and, ultimately, kidney failure, the need of renal replacement therapy (RRT) (namely the end-stage renal disease) and death [1].

In terms of RRT, renal transplantation (RT) reduces disability, and improves kidney function and quality of life, and it also provides greater life expectancy and is more cost-effective compared with dialysis [10,11,12]. In 2008, 547,982 United States residents were treated for end-stage renal disease and 17,413 transplants were performed [13].

The effectiveness of immunosuppressive drugs for maintenance therapy has not been a direct issue regarding the success of RT. Nevertheless, choosing the best suitable immunosuppressive therapy is still fairly complex. Multiple classes of drugs are used in combination. Usually, steroids are administrated with calcineurin inhibitors (CNI) such as cyclosporine (CsA) or tacrolimus (TAC) and either proliferation signal inhibitors (TOR-I) such as sirolimus (SRL) and everolimus (EVL) or antimetabolites (AMETAB) such as azathioprine (AZA) or mycophenolate mofetil (MMF) [14].

Moreover, the balance of advantages and disadvantages is used to determine the regimen of choice, because an increasing range of adverse events must be considered when deciding on the optimal immunosuppressive strategy for an individual patient.

New-onset diabetes mellitus (NODAT) is highly associated with CNI treatment, whereas CMV infection is associated with antimetabolites, and dyslipidemia is associated with TOR-I [14,15]. Thus, it is critical to identify and quantify which adverse events are related to a certain drug regimen as this information is missing in the literature.

Therefore, this systematic review and meta-analysis of randomized controlled trials and observational studies was conducted to evaluate the safety of the most commonly used immunosuppressive regimens. The availability of such information would be useful for clinicians when deciding which treatment is most appropriate for each patient.

2. Literature Search

This systematic review is reported in accordance with Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) [16].

2.1. Eligibility Criteria and Study Selection

Randomized Controlled Trials (RCTs) and cohort studies comparing treatment regimens that included the immunosuppressants azathioprine, cyclosporine, tacrolimus, mycophenolate mofetil or enteric mycophenolate, sirolimus, or everolimus in any dose and with at least 6 months follow-up were included in this analysis. The eligibility criteria for participants included end-stage renal disease patients over age 16 who had undergone renal transplantation for the first time or not, with a living or deceased donor. Only studies published in English, Portuguese or Spanish were included.

Studies with the following characteristics were excluded: (i) enrolled patients younger than 16 years of age; (ii) did not evaluate RT exclusively; (iii) presented pharmacokinetics or pharmacodynamics results; (iv) were single-arm studies; (v) were non-randomized controlled trials; (vi) were placebo controlled studies; (vii) described results from less than 6 months follow-up; (viii) assessed induction therapy; (ix) were health technology assessments studies; and (x) were studies with a conversion of drugs.

The present study focused on the safety of immunosuppressive drugs; thus, studies that did not report safety information were excluded.

2.2. Search Strategy

Several article searches were performed in the Pubmed/MEDLINE, Cochrane Controlled Trials Register, Cochrane’s Renal Group and LILACS databases, covering the period from the inception of the database until August 2013. We also performed a manual search of references that were included in the identified studies and systematic reviews [17,18].

Various combinations of terms were used to search the electronic databases, including terms referring to the disease, interventions and the type of study: “immunosuppression”, “transplant”, “kidney”, “renal”, “azathioprine”, “mycophenolate mofetil”, “cyclosporine”, “tacrolimus”, “sirolimus”, “everolimus”, “effectiveness”, “efficacy” and “safety”.

2.3. Selection of Studies and Data Collection

Two independent reviewers performed the study selection in three phases: analyses of titles, abstracts and full-text articles. A third reviewer resolved disagreements regarding eligibility.

After meticulous reading of all included articles, data were extracted in especially designed manual and electronic forms, using Cochrane Review Manager Software—Revman® 5.1 (The Nordic Cochrane Center, Købehvn, Denmark). The studies were classified according to its treatment strategyarms. Comparison between treatment arms was possible if the schemes contained the same concomitant medication (e.g., steroids) at the same dose, differing only by the drug used as intervention and the control.

Any drug-related adverse event and withdrawals were considered safety outcomes. The overall safety outcomes were collected to extract those most prevalent among them. The data were collected in terms of the number of patients who presented a specific outcome. All consolidated data were reviewed to avoid typing errors.

2.4. Quality Assessment

The quality of the study was independently accessed by two reviewers, and any disagreements were resolved by consensus. Randomized controlled trials were evaluated using the Cochrane Collaboration Tool [19] considering the following items: random sequence generation, allocation concealment, blinding, and incomplete outcome data. Open label studies were not considered risk of bias. Observational studies were evaluated using Newcastle scale [20].

2.5. Data Synthesis and Data Analysis

Outcomes were meta-analyzed if they were reported in at least two articles, within the same treatment arm and at the same time of follow-up. Random effect models were employed to estimate the pooled effect sizes across studies [21]. The results are expressed as the relative risk (RR) with 95% confidence interval (95% CI); p value <0.05 was considered significant. To assess heterogeneity I2 and p values were used (I2 >50% and p < 0.05 indicated high heterogeneity) Publication bias was accessed using funnel plot. Single analysis (estimated RR from raw data) was performed if the data was not eligible to enter in meta-analysis. All analysis was conducted using Revman 5.1.

3. Results

3.1. Study Characteristics

A PRISMA flow chart describing the publication screening process and the reasons for exclusion is shown in Figure 1A total of 5,875 citations identified by the electronic search, and 16 additional articles were identified via manual searching. A total of 48 articles (11,432 participants), from 42 studies, 38 RCTs [22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65] and four cohorts [66,67,68,69] met the inclusion criteria.

Table 1 shows the characteristics of included studies organized by treatment strategy, according to the treatment protocol of each study. CsA was the most prevalent drug in all schemes, as it was used in 34 articles. The majority of studies (33%) compared TAC versus (vs.) CsA, usually using an antimetabolite and a steroid in combination. Within each study, differences between groups in terms of gender, race, age and allograft characteristics were not significant, indicating that the allocation of participants into the treatment groups was satisfactory. Twenty five RCTs were multicenter studies, with the number of centers ranging from 2 to 65 centers. Nearly 50% of the studies were conducted in European countries, 21% of the studies were conducted in the United States, and 14% were conducted in Brazil.

Pharmaceuticals 06 01170 g001 1024
Figure 1. Flow chart of studies included in the systematic review.

Click here to enlarge figure

Figure 1. Flow chart of studies included in the systematic review.
Pharmaceuticals 06 01170 g001 1024

Of the 38 RCT studies evaluating immunosuppressants only 13 (34%) reported adequate sequence generation and most studies did not report the allocation concealment (73%). One study [34] used the numbers of records for randomization and was classified as high risk for selection bias. All studies, but four [22,23,26,40] used intention to treat or modified intention to treat analysis. A summary of RCT quality is shown in Figure 2. The four included cohorts [66,67,68,69] assigned three or four stars in the selection domain, one star in the comparability of groups and one to two in the exposure, demonstrating good quality. Funnel plots of meta-analyses were all symmetrical, indicating the absence of bias.

Pharmaceuticals 06 01170 g002 1024
Figure 2. Quality of RCTs included in the review.

Click here to enlarge figure

Figure 2. Quality of RCTs included in the review.
Pharmaceuticals 06 01170 g002 1024
Table Table 1. Characteristics of included studies.

Click here to display table

Table 1. Characteristics of included studies.
Study (year)TreatmentN (female %)White %First Transplant %Deceased Donor %Cold Ischemia time (SD)Mean Donor Age (SD)Mean Age (SD)Study design, location, time of follow-up and funding
1. CNI vs. CNI
1.Scantleburry (1991) [22]CsA + Pred
TAC + Pred
20
14
NR
NR
100
100
NR
NR
NR
NR
NR
NR
NR
NR
RCT, USA, single center, 12 months
2. Mayer (1997) [23]CsA + AZA + Pred
TAC + AZA + Pred
145 (36.6)
303 (35.3)
NR
NR
89.7
90.4
100
100
NR
NR
43.0
45.2
45.8
46.6
RCT, England, multicenter (15), open label, 12 months, funded by Fujisawa GMBH
3. Yang (1999) [24]CsA + MMF + Ster
TAC + MMF + Ster
30 (37)
30 (50)
87.0
77.0
NR
NR
57.0
67.0
15 (1.6)
14 (1.5)
37 (2.6)
39 (3.0)
48.0 (2.2)
45.0 (2.4)
RCT, USA, single center, open label, 12 months
4. Wang (2000) [25]CsA + MMF + Pred
TAC + MMF + Pred
32
25
NR
NR
NR
NR
100
100
NR
NR
NR
NR
38.1 (18.7)RCT, China, single center, 12 months results
5. Nichelle (2002) [26]CsA + AZA + Ster
TAC + AZA + Ster
46
48
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
RCT, France, single center, 12 and 36 months
6. Campos (2002) [27]CsA
TAC
81 (44)
85 (52)
NR
NR
94
96
52.0
46.0
NR
NR
37.5(14.3)
36.5(13.7)
40.9 (12.3)
40.5 (10.7)
RCT, Brazil, multicenter (15), open label, 12 months
7. Murphy (2003) [28]CsA + Pred + AZA
TAC + Pred + AZA
50 (30.0)
52 (38.5)
NR
NR
88.0
88.0
84.0
82.0
LD:1.7; CAD:19.0;
NHBD:15.5; LD: 2.2;
CAD:18.7; NHBD:15.1
LD:49; CAD:44;
NHBD:48; LD:45;
CAD:39; NHBD:49
45.0 (12.0)
45.0 (14.0)
RCT, England, multicenter (2), open label, 12 months
8. Jurewicz (2003) [66]CsA + AZA + Ster
TAC + AZA + Ster
117
115
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
Cohort, United Kingdom, single center, 72months
9. Hardinger (2005) [29]CsA + AZA + Ster
TAC + AZA + Ster
66 (39)
134 (36)
79
79
100
100
51.0
58.0
12 (4)
13 (5)
NR
NR
44,0 (13.0)
46,0 (13.0)
RCT, USA, single center, open label, 12 months
10. Fukuhara (2005) [67]CsA + Pred
TAC + Pred
137 (36.5)
55 (30.9)
NR
NR
NR
NR
100
100
11.95 (6.12)
12.13 (6.58)
47 (18)
46 (16)
44 (9)
42 (11)
Cohort, Japan, single Center, 10 years
11. Silva (2006) [68]CsA + AZA/MMF
TAC + AZA/MMF
80 (44)
68 (50)
50
53
91
85
100
100
21 (8)
18 (7)
34 (14.0)
34 (12.0)
42 (12.0)
43 (12.0)
Cohort, Brazil, single center, 12 months
12. Silva, Jr. (2007) [30]CsA + Pred
TAC + Pred
TAC XL + Pred
212 (35.5)
212 (35.8)
214 (38.7)
76.9
71.7
74.8
95.8
96.3
96.3
47.6
50.0
51.9
18.44 (7.11)
19.41 (7.27)
17.88 (7.73)
NR
NR
NR
47.6 (13.0)
48.6 (12.9)
47.8 (13.0)
RCT, Brazil, , multicenter (60), open label, 12 months, funded by AstellasPharma US
13. Cheung (2009) [31]CsA + Pred
TAC + Pred
38 (34.2)
38 (44.8)
100a
100a
100
100
100
100
8.7 (4.6)
9.1 (5.1)
48.9 (13.2)
48.9 (13.2)
40.2 (11.7)
41.8 (7.5)
RCT, China, single center, open label, 60 months
14. Vicenti (1996) [32]CsA
TAC
28 (21.4)
92 (34.8)
53.6
51.1
100
100
NR
NR
NR
NR
NR
NR
46.6
44.1
RCT, USA, multicenter (5), open label, 12 months
2. CNI vs. CNI + AMETAB
1. Moreso (1998) [33]CsA + Pred
CsA + MMF(ld) + Pred
CsA + MMF + Pred
CsA(ld) + MMF + Pred
27 (48.2)
27 (44.4)
28 (42.9)
15 (33.3)
NR
NR
NR
NR
37.0
44.4
46.4
93.4
100
100
100
100
NR
NR
NR
NR
41 (16)
41 (18)
42 (17)
44 (14)
47 (15)
45 (14)
43 (15)
47 (7)
RCT, Spain, multicenter (2), double blind in the standard dose CsA groups and open label in the low-dose CsA, 24 months
2. Raofi (1999) [34]CsA + AZA
TAC + Pred
21 (27.7)
14 (22.9)
100b
100b
100
100
100
100
26 (10)
25 (8)
NR
NR
46.0 (11.0)
44.0 (14.0)
RCT, USA, single center, 12 months
3. Sandrini (2000) [35]CsA + Pred
CsA + AZA + Pred
58 (45.0)
58 (38.0)
NR
NR
100
100
100
100
NR
NR
35 (14)
35 (16)
42 (11)
44 (10)
RCT, Italy, single center, 60 months
4. Segoloni (2000) [36] [Pascual (2003)] [37]TAC + Pred
TAC + AZA + Pred
236 (35.2)
239 (35.6)
NR
NR
NR
NR
100
100
18.0
17.6
NR
NR
46.0
45.0
RCT, Italy and Spain, multicenter (36), open label, 12 and 36 months
5. Chang (2001) [38]TAC + Ster
TAC + AZA + Ster
124 (37.9)
121 (32.2)
77,4
76,0
NR
NR
NR
NR
20.4
21.3
NR
NR
48.0
45.0
RCT, United Kingdom, multicenter (08), open label, 12 months
6. Squiflet (2001) [39]TAC + Pred
TAC + MMF(ld) + Pred
TAC + MMF + Pred
82 (46.3)
79 (32.9)
71 (36.6)
93.9
97.5
95.8
86.6
87.3
90.1
100
100
100
NR
NR
NR
45.6 (18.1)
45.6 (16.0)
45.4 (16.9)
46.6 (14.5)
46.5 (13.3)
48.0 (13.3)
RCT, Belgium, multicenter (16), 12 months, funded by Fujisawa
3. CNI vs. AMETAB
1. Hall (1988) [40]CsA
AZA + Pred
138 (42.8)
138 (45.0)
NR
NR
100
100
100
100
22.0
22.7
NR
NR
NR
NR
RCT, Australia, multicenter (7), 36 months, funded by Sandoz
2. Schnuelle (2001) [41]CsA + Ster
MMF + Ster
44 (27.3)
40 (45.0)
NR
NR
95,5
97,5
NR
NR
21.7 (9.0)
21.0 (7.5)
40.7 (15.3)
47.7 (15.4)
44.7 (13.3)
51.3 (11.5)
RCT, Germany, multicenter (3), open label,12 months
3. Hamdy (2008) [42]TAC + SRL + Pred
MMF + SRL + Pred
65 (20.0)
67 (29.8)
NR
NR
100
100
0
0
NR
NR
35.6 (10.3)
36.2 (10.2)
32.3 (10.3)
31.8 (8.6)
RCT, Egypt, single center, 63 months
4. CNI vs. TOR-I
1. Groth (1998) [43]CsA + AZA + Pred
SRL + AZA + Pred
42 (40.0)
41 (29.0)
88.0
98.0
100
100
100
100
17.4 (7.2)
18.9 (7.4)
37.7 (15.9)
44.6 (13.4)
41.6 (11.8)
47.5 (10.8)
RCT, Sweden, multicenter (11), open label, 12 months
2. Büchler (2007)[44]Lebranchu (2012) [45]CsA + MMF + Ster
SRL + MMF + Ster
74 (39.2)
71 (38.0)
95.9
94.4
89.2
95.8
100
100
20.17 (5.46)
19.30 (5.24)
41.3 (14.0)
38.7 (14.4)
45.1 (12.4)
45.6 (10.3)
RCT, France, multicenter (13), 12 months, funded by Wyeth
3. Guba (2010) [46]CsA + MMF + Ster
SRL + MMF + Ster
71
70
98.6
98.6
89.9
94.4
88.4
90.1
13.0 (7.0)
12.1 (5.7)
47.1 (14.3)
46.9 (14.3)
47.1 (11.1)
47.0 (10.8)
RCT, Germany, multicenter (9), 12 months, funded by Wyeth and Fresenius Biotech
4.Glotz (2010) [47]TAC + MMF + Ster
SRL + MMF + Ster
70
71
91.4
77.5
94.3
94.4
100
100
18 (6)
19 (5)
45.1 (12.6)
45.2 (13.4)
46.7 (10.6)
48.5 (9.5)
RCT, France, multicenter (13), 12 months, funded by Wyeth
5. CNI + AMETAB vs. CNI + AMETAB vs. CNI + AMETAB
1. Hernandez (2007) [48]CsA + AZA + Ster
CsA + MMF + Ster
TAC + MMF + Ster
80 (26.2)
80 (37.5)
80 (45.0)
NR
NR
NR
100
100
100
42
50
59
20.3 (4)
21.0 (4)
21 (4)
45 (16)
42 (15)
44 (17)
47 (12)
48 (14)
47 (11)
RCT, Spain, single center, open label, 24 months, funded by Spanish Health Ministry
6. AMETAB vs. AMETAB
1. Keown (1995) [49]AZA + CsA + Pred
MMF + CsA + Pred
MMF(hd) + CsA + Pred
173 (46.2)
166 (33.1)
164 (40.2)
NR
NR
NR
10.4
14.46
10.98
NR
NR
NR
20 (7)
21 (9)
20 (7)
38 (16)
39 (16)
37 (16)
46 (13)
47 (13)
46 (13)
RCT, Canada, multicenter (21), double blind, 24 months
2. Pescovitz (1998) [50]
[Pescovitz (2001)] [51]
AZA + CsA + Ster
MMF + CsA + Ster
108 (40.7)
113 (36.3)
68.5
21.3
87
91
NR
NR
NR
NR
NR
NR
43.7 (11.7)
43.1 (11.6)
RCT, USA, multi centric (15), double blind, 12 and 36 months
3. Folkmane (2002) [52]AZA + CsA + Pred
MMF + CsA + Pred
23
23
NR
NR
NR
NR
100
100
NR
NR
NR
NR
43.2 (12.1)
43.2 (12.1)
RCT, Lithonia, 12 months
4. Sadek (2002) [53]AZA + CsA + Pred
MMF + CsA + Pred
157 (29.0)
162 (40.1)
91.4
90.4
100
100
87
86
NR
NR
NR
NR
43.9 (12.8)
43.9 (13.0)
RCT, United Kingdom, multicenter (28), open label, 12 months, funded by Novartis
7. AMETAB vs. TOR-I
1. Vitko (2004) [54]
[Vitko (2005)] [55]
MMF + CsA
EVR(hd) + CsA
EVR(ld) + CsA
194
198
196
NR
NR
NR
100
100
100
NR
NR
NR
NR
NR
NR
RCT, Czech Republic, multicenter (54), double blind, 12 and 36 months, funded by Novartis
2. Lorber (2005) [56]MMF + CsA + Pred
EVR(hd) + Csa + Pred
EVR(ld) + CsA + Pred
196 (32.7)
194 (36.6)
193 (29.5)
65.8
63.4
70.5
100
100
100
45.9
51.5
52.3
CAD:18.6 (6.42);
LD:1.3 (1.16);
CAD:18.8 (6.43);
LD:1.2 (1.14)
CAD:19.5 (7.18);
LD: 1.4 (3.4)
36.7 (13.81)
38.4 (13.66)
37.4 (13.55)
43.4
43.7
43.3
RCT, Switzerland, multicenter (44), 36 months, funded by Novartis
3. Mendez (2005) [57]MMF + TAC + Pred
SRL + TAC + Pred
176 (30.1)
185 (33.5)
54.0
50.8
NR
NR
64.2
63.2
19.8
19.1
NR
NR
47.8 (12.3)
45.3 (12.4)
RCT, USA, multicenter (27),open label, 12 months, funded by Fujisawa
4. Sampaio (2007) [58]MMF + TAC + Pred
SRL+TAC+Pred
50 (24.0)
50 (38.0)
54.0
42.0
100
100
24.0
24.0
NR
NR
41.9 (10.5)
41.6 (10.0)
42.6 (14.2)
37.4 (10.3)
RCT, Brazil, single center, open label, 12 months, funded by Janssen-Cilag
5. Tedesco-Silva (2010) [59];
Cibrik (2013) [60]
MMF
EVR
EVR(ld)
277 (31.8)
279 (31.5)
277 (36.5)
68.6
64.5
69.7
100
100
100
46.2
45.9
46.6
NR
NR
NR
41.8 (13.6)
41.1 (13.0)
41.4 (13.9)
47.2 (12.7)
45.3 (13.4)
45.7 (12.7)
RCT, Brazil, multicenter, open label, 12 and 24 months, funded by Novartis
8. CNI vs. CNI vs. TOR-I
1. Ekberg (2007) [61];
Ekberg (2009) [62]
CsA(sd) + MMF + Ster
CsA(ld) + MMF + Ster
TAC(ld) + MMF + Ster
SRL(ld) + MMF + Ster
384 (37.7)
408 (33.6)
403 (34.2)
380 (33.3)
92.1
92.2
94.0
94.2
NR
NR
NR
NR
65.6
64.2
62.8
64.2
16.6 (5.5)
16.8 (5.2)
16.5 (5.7)
16.0 (5.8)
44.6 (15.9)
46.2 (15.1)
45.2 (15.5)
46.0 (14.8)
45.9 (13.8)
47.2 (13.5)
45.4 (14.7)
44.9 (14.5)
RCT (12 months) and Cohort (36 months), Sweden, multicenter (15), open label, 12 and 36 months, funded by Hoffman-La Roche
9. CNI+AMETAB vs. CNI+TOR-I
1.Kumar (2005) [63]CsA + MMF
CsA + SRL
TAC + MMF
TAC + SRL
58
52
50
40
AA = 0
N − AA = 89
AA = NR
Non – AA = NR
AA = 93
n − AA= 83
AA = 15.5 (6.8)
n − AA = 15.9 (12.1)
AA = 42.0 (16.5)
N − AA = 42.3 (19.2)
AA = 52.9 (12.0)
n − AA = 53.0 (15.6)
RCT, USA, single center, 12 months
10. TOR-I vs. CNI+TOR-I
1. Tedesco-Silva (2010) [64]SRL
SRL+CsA
102 (36.3)
105 (36.2)
72.6
62.9
98.0
98.1
31.4
30.5
7.36 (0.99)
7.64 (1.03)
NR
NR
41.5
40.9
RCT, Brazil, multicenter (9), open label, 12 months, funded by Wyeth
11. CNI+AMETAB vs. CNI vs. AMETAB
1. Gheith (2008) [69]CsA + AZA + Pred
CsA + Pred
AZA + Pred
239 (26.36)
75 (42.67)
130 (26.92)
NR
NR
NR
NR
NR
NR
0
0
0
NR
NR
NR
34.0 (9.2)
34.6 (10.3)
33.3 (10.1)
30.7 (10.1)
28.1 (10.3)
29.8 (7.9)
Cohort, Egypt, single Center, 20 years
12. TOR-I + CNI-Elim vs. TOR-I vs. CNI
1. Flechner (2011) [65]SRL + TAC-Elim
SRL + MMF
TAC + MMF
152 (28.3)
152 (27.6)
139 (41.7)
75.0
77.0
73.4
92.8
91.5
92.1
60.5
63.2
64.0
17.7 (6.7)
17.3 (5.7)
17.4 (6.3)
43.2 (13.6)
45.5 (14.9)
44.4 (13.9)
47.9 (13.3)
50.4 (13.0)
48.4 (13.2)
RCT, USA, multicenter (65), open-label, 24 months, funded by Wyeth

Abbreviations: AMETAB, Antimetabolites; CAD, Cadaveric donor; Elim, elimination; LD, Living donor; NHBD, Non-heart beating donor; NR, not reported; Pred, Prednisone; Ster, Steroids; (ld), Low dose; (sd), Standard dose; (hd), High dose. The study compares AA (African American) and n-AA (non-African American) recipients

3.2. Outcomes

All adverse events reported in the included articles were collected, and the most prevalent events were included in the synthesis. The following outcomes were included: abdominal pain, anemia, bacterial infections (all definitions), cytomegalovirus (CMV) infections, diabetes mellitus (new-onset diabetes mellitus, post-transplant diabetes, and use of hypoglycemic drugs were considered), diarrhea, dyslipidemia (hypercholesterolemia, hypertriglyceridemia and hyperlipidemia were considered), gastritis, total infections (as reported in the study), hypertension (use of antihypertensive drugs was also considered), leukopenia, lymphoceles, malignancies (all types), nausea, vomiting, thrombocytopenia, urinary tract infection (UTI) and withdrawal (discontinuation and crossover of study medication were considered).

For data synthesis and analysis, the comparable schemes in each study were classified into the following groups: CNI vs. CNI; AMETAB vs. AMETAB;TOR-I vs. CNI; CNI + AMETAB vs. CNI; TOR-I vs. AMETAB; and AMETAB vs. CNI. In some studies, it was possible to compare more than one group, such as studies that included the treatment protocol of CNI + AMETAB vs. CNI + AMETAB vs. CNI + AMETAB (it was possible to compare CNI vs. CNI and AMETAB vs. AMETAB).

3.2.1. CNI vs. CNI

All studies that compared CsA and TAC were included in this group. A total of 17 articles [22,23,24,25,26,27,28,29,30,31,32,48,61,62,66,67,68] reported safety data related to TAC as the experimental treatment and CsA as the control. One study used low-dose TAC (3–7 ng/mL) and low-dose CsA (50–100 ng/mL) [61,62], whereas the others used standard doses of both drugs (5–15 ng/mL for TAC and 150–300 ng/mL for CsA).

The results of 13 articles, two cohorts and 11 RCTs, were meta-analyzed and are displayed in Table 2. Both the cohort and RCT pooled results indicate that TAC was associated with an increased risk for diabetes (Figure 3). This association was also found at 120 months follow-up in one cohort that was not included in the pooled analysis (n = 192; RR = 2.10; 95% CI: 1.17, 3.77; p = 0.01) [67]. The risk of dyslipidemia was reduced in TAC regimens, as shown in the meta-analysis and in two single studies: a cohort of 36 months (n = 506; RR = 0.74; 95% CI: 0.57, 0.97; p = 0.03) [62] and a RCT of 60 months (n = 76; RR = 0.62; 95% CI: 0.40, 0.95; p = 0.03) [31].

Although the other outcomes had no statistical significance in the pooled results, studies in single analysis showed that TAC was associated with a higher risk of withdrawing the treatment at 120 months of follow-up (n = 192; RR = 11.21; 95% CI: 2.50, 50.23; p = 0.002) [67] and that CsA presented a greater risk for hypertension at 36 months of follow-up (n = 89; RR = 0.67; 95% CI: 0.48, 0.94; p = 0.02) [26].

Table Table 2. Meta-analysis results of outcomes reported by studies comparing TAC vs. CsA a.

Click here to display table

Table 2. Meta-analysis results of outcomes reported by studies comparing TAC vs. CsA a.
OutcomeStudy Design (N)Time in monthsRelative Risk b (95% CI)Statistics c
pI2
CMVRCT [23,24,29,61] (1519)120.85 (0.64, 1.15)0.300
DiabetesRCT [22,23,24,25,27,28,29,30,32,61] (2389)121.72 (1.17, 2.52)0.00635
Cohort [62,66] (738)362.71 (1.61, 4.57)0.00020
Dyslipidemia RCT [29,30,61] (1435)120.75 (0.60, 0.94)0.010
Hypertension RCT [23,26,27,29,61] (1714)120.97 (0.82, 1.16)0.7625
Total Infections RCT [23,24,25,61] (1376)121.03 (0.93, 1.14)0.5512
Lymphoceles RCT [30,61] (1235)120.61 (0.34, 1.07)0.0910
Malignancies RCT [23,29,61] (1459)121.16 (0.40, 3.38)0.790
Withdraw RCT [23,24,27,28,29,30,32,61] (2384)120.98 (0.34, 2.81)0.9782 *

a Results reaching statistical significance are in bold font. b Relatives risk values of <1 favor treatment with TAC. c p: p-value for relative risk estimation; I2: test for heterogeneity. * The high heterogeneity (p < 0.00001) could be caused by the following trials: Mayer 1997 [23], Hardinger 2005 [29] and Vicenti 1996 [32]. Sensitivity analysis showed much reduced heterogeneity (p = 0.23, I2 = 29%) when these trials were removed from the analysis.

Pharmaceuticals 06 01170 g003 1024
Figure 3. Meta-analysis of diabetes for TAC vs. CsA comparison at 12 and 36 months.

Click here to enlarge figure

Figure 3. Meta-analysis of diabetes for TAC vs. CsA comparison at 12 and 36 months.
Pharmaceuticals 06 01170 g003 1024

* The study of Ekberg is a RCT with 12 months of experimental data and 36 months of observational data, so that the article containing results at 36 months results was included in cohort analysis.

3.2.2. AMETAB vs. AMETAB

Five articles from four RCTs with 12 months of follow-up compared AZA (control) with MMF (intervention) [49,50,51,52,53]. The dosage used in the studies ranged from 100–150 mg/day for AZA and 2–3 g/day for MMF.

All five articles were included in meta-analysis and the results are shown in Table 3. MMF was associated with an increased risk for total infections and gastrointestinal discomfort, including abdominal pain, diarrhea and vomiting. The sensitivity analysis for heterogeneity indicated that participants who were taking MMF had a higher risk of withdrawing from the treatment.

Table Table 3. Meta-analysis results of outcomes reported by studies comparing MMF vs. AZA a.

Click here to display table

Table 3. Meta-analysis results of outcomes reported by studies comparing MMF vs. AZA a.
OutcomeStudy Design (N)Time in monthsRelative Risk bStatistics c
(95% CI)pI2
Total Infections RCT [49,51,52,53] (919)121.17 (1.03, 1.33)0.010
CMV RCT [49,51,52,53] (919)120.94 (0.82, 1.03)0.1741
Abdominal pain RCT [49,50,53] (873)121.40 (1.06, 1.83)0.0214
Diarrhea RCT [49,50,53] (873)121.49 (1.17, 1.90)0.00110
Nausea RCT [49,50,53] (873)120.98 (0.69, 1.39)0.9141
Vomiting RCT [49,50,53] (873)121.54 (1.10, 2.15)0.010
Malignancies RCT [49,53] (652)121.52 (0.81, 2.82)0.190
Withdraw RCT [49,50,53] (873)121.21 (0.77, 1.92)0.4066*

a Results reaching statistical significance are in bold font. b Relatives risk values of <1 favor treatment with MMF. c p: p-value for relative risk estimation;I2: test for heterogeneity. * RCT Sadek 2002 [53] is largely responsible for the heterogeneity among RCTs that reported withdraw. Sensitivity analysis showed a relative risk of 1.93 (1.06 to 3.52), and dramatically reduced heterogeneity (p =0.95, I2 = 0%) when this trial was removed from the analysis.

3.2.3. TOR-I vs. CNI

Eight articles from five RCTs with 12 months of follow-up and one RCT of 24 months were included in this group: two accessing SRL vs. TAC [47,65], four accessing SRL vs. CsA [43,44,45,46] and two accessing both [61,62]. In these studies, SRL was used at low (4–8 ng/mL) and standard (10–20ng/mL) doses, as well as CsA, whereas TAC was administered only at low dose. SRL was applied as experimental drug and CsA and TAC served as controls.

Five articles were included in the meta-analysis (Table 4). When compared with any of the CNIs, the use of SRL presented a higher risk for anemia, dyslipidemia, lymphoceles and withdrawal. The association between SRL and anemia was also reported by one cohort of 36 months, which was not included in the pooled analysis, compared with CsA (n = 476; RR = 1.30; 95% CI: 1.05, 1.60; p = 0.02) and TAC (n = 472; RR = 1.29; 95% CI: 1.05, 1.60; p = 0.02) [62]. A similar result was observed for dyslipidemia when SRL was compared with TAC (n = 472; RR = 1.42; 95% CI: 1.15, 1.76; p = 0.001) [62]. Single analysis of a RCT comparing SRL and TAC at 24 months showed similar results with the SRL vs. TAC meta-analysis: SRL was associated with increased risk of anemia, dyslipidemia, lymphoceles and withdrawal, and had no difference for malignancy, infections or hypertension [65]. Moreover, the risk of diabetes was higher for SRL, and the risk of CMV infection was higher for CsA.

Table Table 4. Meta-analysis results of outcomes reported by studies comparing SRL vs. CsA or TAC a.

Click here to display table

Table 4. Meta-analysis results of outcomes reported by studies comparing SRL vs. CsA or TAC a.
SRL vs. CsASRL vs. TAC
OutcomeStudy Design (N)Time (mo.)Relative Risk b (95% CI)Statistics cStudy Design (N)Time (mo.)Relative Risk b (95% CI)Statistics c
pI2%pI2%
Total Infections RCT [46,61] (927)120.98 (0.82, 1.18)0.8633
CMV RCT [43,44,46,61] (1,155)120.46 (0.25, 0.85)0.0153 dRCT [47,61] (924)120.26 (0.03,2.30)0.2379
UTI RCT [43,44,46,61] (1,155)121.04 (0.79, 1.37)0.7935
Anemia RCT [43,46,61] (1,010)121.48 (1.16, 1.90)<0.010RCT [47,61] (924)121.56 (1.26,1.93)<0.010
Leukopenia RCT [43,46,61] (1,010)121.32 (0.70, 2.47)0.3957 eRCT [47,61] (924)120.82 (0.59,1.14)0.240
Dyslipidemia RCT [43,46,61] (1,010)122.02 (1.03, 3.97)0.0465 fRCT [47,61] (924)121.58 (1.10,2.26)0.010
Diabetes RCT [43,44,46,61] (1,155)121.82 (1.14, 2.89)0.050RCT [47,61] (924)120.78 (0.52,1.17)0.230
Hypertension RCT [43,46,61] (1,010)120.94 (0.66, 1.33)0.7128RCT [47,61] (924)121.53 (0.55,4.23)0.4193
Lymphoceles RCT [44,46,61] (1,072)121.65 (1.10, 2.46)0.0118RCT [47,61] (924)122.92 (1.73,4.93)<0.010
Malignancies RCT [43,61] (871)121.09 (0.09,13.46)0.9560
Withdraw RCT [43,44,46,61] (1,155)123.68 (2.22, 6.11)<0.010RCT [47,61] (924)124.31 (2.32,7.99)<0.010

Abbreviations: UTI, urinary tract infection. a Results reaching statistical significance are in bold font. b Relatives risk values of <1 favor treatment with SRL. c p: p-value for relative risk estimation; I2: test for heterogeneity. d Sensitivity analysis removing Groth 1998 [43]: RR 0.38 (0.21 to 0.67; I2 = 38%). e Sensitivity analysis removing Groth 1998 [43]: RR 1.0 (0.69 to 1.47; I2 = 0%). f Sensitivity analysis removing Ekberg 2007 [61]: RR 3.01 (1.61 to 5.62; I2 = 0%).

Lebranchu et al. (2012) reported the 5-years results of the RCT from Buchler et al. [44], which compared SRL vs. CsA, and reported outcomes as mouth ulcers, acne, UTI, malignancies, diabetes and withdrawal due to adverse event, but none showed difference between groups in single analysis [45].

One RCT with 12 months of follow-up compared SRL in combination with CsA vs. SRL alone [64] and reported anemia, hypertension, CMV infection, lymphoceles, dyslipidemia, diabetes and polycythemia; however, only polycythemia was associated with the combination of TOR-I and CNI (n = 207; RR = 3.40; 95% CI: 1.16, 9.98; p = 0.03).

3.2.4. CNI + AMETAB vs. CNI

Seven studies were included in this group: one cohort with 240 months of follow-up comparing CsA+AZA vs. CsA [69], one RCT with 12 months of follow-up comparing CsA + MMF vs. CsA [33], three RCTs with 12 and 36 months of follow-up comparing TAC + AZA vs. TAC [36,37,38], one RCT with 12 months of follow-up comparing TAC + MMF vs. TAC [39] and one RCT with 12 months of follow-up comparing CsA + AZA vs. TAC [34]. CsA and MMF were administrated at both low and standard doses, whereas TAC and AZA were used only at the standard dose.

Two studies comparing TAC + AZA vs. TAC at 12 months of follow-up were meta-analyzed and the results are displayed on Table 5. The meta-analysis revealed that the combination of TAC and AZA was associated with a greater risk of leukopenia and withdrawal compared with TAC alone. The RCT with 36 months of follow-up confirmed this result for leukopenia (n = 475; RR = 5.60; 95% CI: 2.39, 13.08; p < 0.01) [37]. In a single analysis, the combination of TAC and AZA was associated with anemia at 12 months of follow-up (n = 475; RR = 1.55; 95% CI: 1.06, 2.28; p = 0.02) [36].

Table Table 5. Meta-analysis results of outcomes reported by studies comparing TAC + AZA vs. TAC a.

Click here to display table

Table 5. Meta-analysis results of outcomes reported by studies comparing TAC + AZA vs. TAC a.
OutcomeStudy Design (N)Time in monthsRelative Risk b (95% CI)Statistics c
pI2
Total Infections RCT [36,38] (720)120.99 (0.82, 1.20)0.940
Leukopenia RCT [36,38] (720)128.41 (3.36, 21.02)<0.010
Diabetes mellitus RCT [36,38] (720)120.85 (0.41, 1.76)0.670
Hypertension RCT [36,38] (720)120.83 (0.65, 1.06)0.130
Tremor RCT [36,38] (720)120.96 (0.68, 1.35)0.820
Withdraw RCT [36,38] (720)1210.39 (4.40, 24.56)<0.010

a Results reaching statistical significance are in bold font. b Relatives risk values of <1 favor treatment with Antiproliferative Agent + TAC. c p: p-value for relative risk estimation; I2: test for heterogeneity

The combination of TAC and MMF at 12 months was associated with a greater risk of gastritis (n = 135; RR = 1.92; 95% CI: 1.18, 3.14; p = 0.009) and leukopenia (n = 153; RR = 3.00; 95% CI: 1.13, 8.01; p = 0.03) [39], compared with TAC alone.

The combination of CsA and AZA at 240 months of follow-up was associated with higher risk for hypertension (n = 314; RR = 1.23; 95% CI: 1.04, 1.46; p = 0.02) and a lower risk for bacterial infections (n = 314; RR = 0.31; 95% CI: 0.13, 0.76; p = 0.01), compared to CsA alone [69]. The studies comparing CsA + MMF vs. CsA and TAC + MMF vs. TAC reported CMV infection, diabetes, diarrhea and leukopenia but the estimated RRs were not significant.

3.2.5. TOR-I vs. AMETAB

Seven RCTs were included in this group: four comparing EVL vs. MMF, at 12 months [54,59], 24 months [60], and 36 months of follow-up [55,56] and three comparing SRL vs. MMF at 12 months [57,58] and 24 months of follow-up [63]. SRL and MMF were used at standard doses, and EVL was used at low (1.5 mg/day) and high (3 mg/day) doses.

The studies comparing EVL and MMF were meta-analyzed in subgroups of 12 and 36 months of follow-up and divided based on low- and high-dose EVL (Table 6). Additionally, the studies comparing SRL and MMF at 12 months of follow-up were meta-analyzed. No differences were observed when comparing low- and high-dose EVL. Independent of dosing, EVL was associated with an increased risk of dyslipidemia and withdrawal. MMF presented a higher risk of CMV infection when compared with both doses of EVL. The single analysis for 24 months of follow-up showed similar results: both doses of EVL were associated with increased risk of withdrawal and lower risk of CMV infection and leukopenia when compared with MMF [60]. In the same study, high-dose EVL was associated with a greater risk of diabetes (n = 833; RR = 1.96; 95% CI: 1.18, 1.87; p = 0.01) [60]. Compared with MMF, SRL showed increased risk of withdrawal in meta-analysis and no significant results were found in single-analysis.

3.2.6. AMETAB vs. CNI

Three studies compared an antimetabolite with a CNI: one RCT with 63 months of follow-up that compared MMF vs. TAC [39] and two studies comparing AZA vs. CsA, a cohort with 240 months of follow-up [69] and a RCT with 36 months of follow-up [40]. All drugs were used at standard doses.

There was not a sufficient number of studies with identical follow-up periods to perform meta-analysis. The risk for dyslipidemia (n = 132; RR = 1.75; 95% CI: 1.13, 2.71; p = 0.01) and diarrhea (n = 132; RR = 3.87; 95% CI: 1.35, 11.03; p = 0.01) was higher for MMF, compared with TAC, and MMF presented a lower risk of withdrawal than TAC (n = 132; RR = 0.14; 95% CI: 0.04, 0.45; p = 0.0009) [39].

AZA was associated with an increased risk of pulmonary infections (n = 276; RR = 2.25; 95% CI: 1.01, 5.00; p = 0.05) and leukopenia (n = 276; RR = 2.76; 95% CI: 1.86, 4.08; p < 0.01) [40] and a lower risk of hypertension (n = 205; RR = 0.77; 95% CI: 0.61, 0.97; p = 0.03) [69].

4. Conclusions

Six different groups of immunosuppressant drugs were evaluated and compared. Evaluating the safety of immunosuppressive drugs is complex because kidney transplantation requires the simultaneous use of multiple classes of drugs at varying doses.

The majority of the studies included here showed a low risk of bias, and only one study revealed a high risk of bias for allocation order generation and allocation confidentiality [34]. Based on the parameters described in the Cochrane Handbook [19], the quality of most studies was compromised by a lack of sufficient information to judge the randomization and allocation concealment.

However, this quality assessment did not invalidate the results of the meta-analysis. Overall, the heterogeneity of the treatment-efficacy results was low, indicating small inter-study variability. In general, the observational studies did not show selection bias, and the majority of these studies used the same time in and out of treatment, allowing for a comparison of populations.

Table Table 6. Meta-analysis results of outcomes reported by studies comparing EVL or SRL vs. MMF a.

Click here to display table

Table 6. Meta-analysis results of outcomes reported by studies comparing EVL or SRL vs. MMF a.
OutcomeEVL (ld) vs. MMF EVL (hd) vs. MMF SRL vs. MMF
Study Design (N)Time (mo.)Relative Risk b (95% CI)Statistics cStudy Design (N)Time (mo.)Relative Risk b (95% CI)Statistics cStudy Design (N)Time (mo.)Relative Risk b (95% CI)Statistics c
pI2pI2pI2
Total InfectionsRCT [54,59] (946)120.62 (0.26, 1.48)0.2892RCT [54,59] (946)120.83 (0.58, 1.18)0.2970
CMV infectionsRCT [54,59] (946)120.23 (0.12, 0.42)<0.010RCT [54,59] (946)120.15 (0.01, 2.17)0.1673
RCT [55,56] (781)360.47 (0.16, 1.41)0.1878RCT [55,56] (780)360.47 (0.29, 0.74)<0.010
AnemiaRCT [54,59] (946)120.97 (0.79, 1.20)0.800RCT [54,59] (946)121.15 (0.95, 1.40)0.150
RCT [55,56] (781)361.17 (0.73, 1.88)0.5076RCT [55,56] (780)361.47 (0.97, 2.23)0.0774
LeukopeniaRCT [55,56] (781)360.50 (0.24, 1.06)0.0742
DyslipidemiaRCT [54,59] (946)121.68 (1.01, 2.79)0.0568RCT [54,59] (946)121.63 (1.08, 2.46)0.0252
HypertensionRCT [54,59] (946)120.98 (0.73, 1.32)0.870RCT [54,59] (946)120.97 (0.80, 1.18)0.780
LymphocelesRCT [55,56] (781)361.54 (0.96, 2.45)0.0714RCT [55,56] (780)362.08 (1.00, 4.32)0.0563
WithdrawRCT [55,56] (781)361.23 (1.07, 1.43)0.0050RCT [55,56] (780)361.41 (1.23, 1.62)<0.010RCT [57,58] (459)121.81 (1.20, 2.72)0.0040

Abbreviations: (ld), Low dose; (hd), High dose; mo., months. a Results reaching statistical significance are in bold font. b Relatives risk values of <1 favor treatment with TOR-I. c p: p-value for relative risk estimation; I2: test for heterogeneity.

Compared with CsA, treating kidney transplant patients with TAC resulted in a higher risk for diabetes, whereas those taking CsA had a greater risk of developing dyslipidemia. A retrospective study of risk factors for new-onset diabetes after transplantation (NODAT) found that higher tacrolimus concentrations were an independent predictor of NODAT [70]. In a meta-analysis comparing TAC vs. CsA as the primary immunosuppressant for kidney transplant recipients, TAC-treated patients were two to three times more likely to develop new diabetes mellitus that required insulin. However, the adverse events associated to CsA (constipation, hirsutism, and gingival hyperplasia) were different from those that we found, likely due to the time of use [16].

In regard to MMF vs. AZA, the majority of studies reported a larger number of adverse events for the groups treated with MMF at 12 months of follow-up. The meta-analyses of total infections, vomiting, diarrhea, and abdominal pains statistically favored treatment with AZA. The results of the present meta-analysis agree with the findings of a systematic review conducted in 2009 [71], which found that MMF-treated patients had a greater risk of diarrhea, whereas the risks of CMV infection, anemia, leukopenia and malignancy were not significant.

Our results showed that the use of SRL was associated with higher risk for anemia, dyslipidemia, lymphoceles and withdrawal compared with any CNI. There were no significant differences for infections, UTI, leukopenia, hypertension, or malignancies. These results agree with the findings of a multicenter study which used TAC in combination with different doses of SRL and showed that the incidence of dyslipidemia (hypercholesterolemia) was associated with higher doses of SRL [72]. Another study comparing TOR-I versus CNI found an increased risk of bone marrow suppression outcomes (leukopenia, thrombocytopenia, and anemia), lymphoceles and dyslipidemia for patients taking SRL [73]. Compared with CsA, SRL presented a higher risk for diabetes and reduced risk of CMV infection. Although regimens containing SRL have a higher risk of post-transplant diabetes than regimens without SRL [74], TAC has a higher risk for diabetes than CsA, thus the difference of risk between TAC and SRL may have no significance. Johnston et al. compared SRL with TAC and with CsA and found that patients treated with CsA had the lowest incidence of diabetes (15.6%), followed by SRL (17.8%) and then TAC (19%) [74]. Sirolimus in combination with CNI may increase clinically significant adverse events, such as CNI-related nephrotoxicity and dyslipidemia. Other outcomes include hematologic side effects and a higher incidence of lymphoceles [75]. Furthermore, the use of SRL combined with TAC might increase the risk of post-transplant diabetes mellitus [17,76].

As the majority of studies comparing TOR-I with CNI assess CNI minimization or elimination thru conversion from CNI to TOR-I, the number of studies with such comparison included in the present review was limited, once conversion of drugs was considered exclusion criteria.

Independent of the dose, EVL was associated with increased risk of dyslipidemia and withdrawal. MMF presented higher risk of CMV infection compared with both doses of EVL, but there was no difference in bone marrow suppression (leukopenia and anemia), hypertension, lymphoceles and infections. According to one study, SRL and MMF are associated with similar incidences of both leukopenia and thrombocytopenia [77]. This study reported similar incidences of leukopenia with the combination of MMF and SRL and MMF alone, and similar incidences of thrombocytopenia were observed between their combination and SRL alone, indicating no difference in the risk of these outcomes [77]. The definitions of diabetes and other diseases, such malignancies and dyslipidemia, vary a lot between studies, thus the interpretation of results regarding these diseases should consider the differences between definitions. Many of the clinical trials included were funded by pharmaceutical industries, limiting the interpretation of results, as these companies may benefit from reporting only favorable findings.

Current immunosuppressive protocols use combinations of immunosuppressive agents with different mechanisms of action to maximize efficacy and minimize the toxicity of each drug. The appearance of new immunosuppressive agents and tolerance protocols emerge shows potential as a means to deliver immunosuppression without long-term toxicity. In this regard, belatacept is a second-generation costimulation blocker that in phase 3 trials was to provide effective immunosuppression while avoiding the toxicities associated with calcineurin inhibitors [78].

Modifications are still being introduced in immunosuppressant protocols to take advantage of the drugs’ beneficial actions and to reduce the adverse events. Although safety information alone is not enough to base decision making in health, together with reliable information about the long-term efficacy of immunosuppressants, the results of the present review might assist healthcare professionals and managers in choosing the best immunosuppressant regimen. We concluded that the data examined in this meta-analysis are similar to those describe by others authors. Adverse reactions were observed in all classes of immunosuppressive drugs; thus the choice of treatment must be made by the clinical staff based on specific patient characteristics.

Acknowledgments

The authors are grateful to the team of the Research Group in Pharmacoepidemiology (GPFE). This work received financial support from the Brazilian Ministry of Health and the Brazilian National Council for Scientific and Technological Development (CNPq).

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Levey, A.S.; Coresh, J.; Balk, E.; Kausz, A.T.; Levin, A.; Steffes, M.W.; Hogg, R.J.; Perrone, R.D.; Lau, J.; Eknoyean, G. National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann. Intern. Med. 2003, 139, 137–147. [Google Scholar] [CrossRef]
  2. Coresh, J.; Selvin, E.; Stevens, L.A.; Manzi, J.; Kusek, J.W.; Eggers, P.; van Lente, F.; Levey, A.S. Prevalence of chronic kidney disease in the United States. JAMA 2007, 298, 2038–2046. [Google Scholar] [CrossRef]
  3. Zhang, Q.L.; Rothenbacher, D. Prevalence of chronic disease in population-based studies: Systematic review. BMC Public Health 2008, 8, 117. [Google Scholar] [CrossRef]
  4. Nagata, M.; Ninomiya, T.; Doi, Y.; Yonemoto, K.; Kubo, M.; Hata, J.; Tsuruya, K.; Iida, M.; Kiyohara, Y. Trends in the prevalence of chronic kidney disease and its risk factors in a general Japanese population: The Hisayama study. Nephrol. Dial. Transplant. 2010, 25, 2557–2564. [Google Scholar] [CrossRef]
  5. Van Pottelbergh, G.; Bartholomeeusen, S.; Buntinx, F.; Degryse, J. The prevalence of chronic kidney disease in a Flemish primary care morbidity register. Age Ageing 2011, 41, 231–233. [Google Scholar]
  6. Muntner, P.; Newsome, B.; Kramer, H.; Peralta, C.A.; Kim, Y.; Jacobs, D.R., Jr.; Kiefe, C.I.; Lewis, C.E. Racial Differences in the Incidence of Chronic Kidney Disease. Clin J. Am. Soc. Nephrol. 2011, 7, 101–107. [Google Scholar]
  7. McCullough, K.; Sharma, P.; Ali, T.; Khan, I.; Smith, W.C.S.; MacLeod, A.; Black, C. Measuring the population burden of chronic kidney disease: A systematic literature review of the estimated prevalence of impaired kidney function. Nephrol. Dial. Transplant. 2012, 27, 1812–1821. [Google Scholar] [CrossRef]
  8. Levey, A.S.; Atkins, R.; Coresh, J.; Cohen, E.P.; Collins, A.J.; Eckardt, K.U.; Nahas, M.E.; Jaber, B.L.; Jadoul, M.; Levin, A.; et al. Chronic kidney disease as a global public health problem: Approaches and initiatives—A position statement from Kidney Disease Improving Global Outcomes. Kidney Int. 2007, 72, 247–259. [Google Scholar] [CrossRef]
  9. Cusumano, A.M.; Gonza´lez Bedat, M.C. Chronic Kidney Disease in Latin America: Time to improve screening and detection. Clin. J. Am. Soc. Nephrol. 2008, 3, 594–600. [Google Scholar] [CrossRef]
  10. Port, F.K.; Wolfe, R.A.; Mauger, E.A.; Berling, D.P.; Jiang, K. Comparison of survival probabilities for dialysis patients vs. cadaveric renal transplantation recipients. JAMA 1993, 270, 1339–1343. [Google Scholar] [CrossRef]
  11. Evans, R.W.; Manninen, D.L.; Garrison, L.P.; Hart, L.G; Blagg, C.R.; Gutman, R.A.; Hull, A.R.; Lowrie, E.G. The quality of life of patients with end-stage renal disease. N. Engl. J. Med. 1985, 312, 553–559. [Google Scholar] [CrossRef]
  12. Eggers, P.W. Effect of transplantation on the Medicare End-Stage Renal Disease Program. N. Engl. J. Med. 1988, 318, 223–229. [Google Scholar] [CrossRef]
  13. National Kidney and Urologic Diseases Information Clearinghouse. Kidney and Urologic Diseases Statistics for the United States. Available online: http://kidney.niddk.nih.gov/kudiseases/pubs/kustats/ (accessed on 1 May 2012).
  14. Kidney Disease: Improving Global Outcomes (KDIGO). Clinical practice guideline for the care of kidney transplant recipients. Am. J. Transplant. 2009, 9, S1–S155.
  15. Sprangers, B.; Kuypers, D.R.; Vanrenterghem, Y. Immunosuppression: Does on regimen fit all? Transplantation 2011, 92, 251–261. [Google Scholar] [CrossRef]
  16. Liberati, A.; Altman, D.G.; Tetzlaff, J.; Mulrow, C.; Gotzsche, P.C.; Loannidis, J.P.A.; Clarke, M.; Devereaux, J.K.; Moher, D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. PLoS Med. 2009, 6, 7:1–7:28. [Google Scholar]
  17. Woodroffe, R.; Yao, G.L.; Meads, C.; Bayliss, S.; Ready, A.; Raftery, J.; Taylor, R.S. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: A systematic review and modelling study. Health Technol. Assess. 2005, 9, 21:1–21:179. [Google Scholar]
  18. Webster, A.C.; Woodroffe , R.C.; Taylor, R.S.; Chapman, J.R.; Craig, J.C. Tacrolimo versus ciclosporin as primary immunosuppression for kidney transplant recipients: Meta-analysis and meta-regression of randomised trial data. BMJ 2005, 331, 810:1–810:11. [Google Scholar]
  19. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. Available online: www.cochrane-handbook.org/ (accessed on 24 June 2013).
  20. Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomized Studies in Meta-analyses. Available online: http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm/ (accessed on 6 August 2010).
  21. Higgins, J.P.T.; Thompson, S.G.; Deeks, J.J.; Altman, D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327, 557–560. [Google Scholar] [CrossRef]
  22. Scantleburry, V.; Shapiro, R.; Fung, J.; Tzakis, A.; McCauley, J.; Jordan, M.; Jensen, C.; Hakala, T.; Simmons, R.; Starzi, T.E. New onset of diabetes in FK 506 vs. cyclosporine-treated kidney transplant recipients. Transplant. Proc. 1991, 23, 3169–3170. [Google Scholar]
  23. Mayer, A.D.; Dmitrewski, J.; Squifflet, J.P.; Bese, T.; Grabensee, B.; Klein, B; Eigler, F.W.; Heemann, U.; Pichlmayr, R.; Behrend, M. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: A report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 1997, 64, 436–443. [Google Scholar] [CrossRef]
  24. Yang, H.C.; Holman, M.J.; Langhoff, E.; Ulsh, P.J.; Dellock, C.A.; Gupta, M.; Ahsan, N. Tacrolimus/“low-dose” mycophenolate mofetil versus microemulsion cyclosporine/“low-dose” mycophenolate mofetil after kidney transplantation: 1-year follow-up of a prospective, randomized, clinical trial. Transplant. Proc. 1999, 31, 1121–1124. [Google Scholar] [CrossRef]
  25. Wang, X.H.; Tang, X. D.; Xu, D. Tacrolimus vs. Cya Neoral in Combination with MMF and steroid after cadaveric renal transplantation. Transplant. Proc. 2000, 32, 1702–1703. [Google Scholar] [CrossRef]
  26. Nichelle, L.; Canet, S.; Garrigue, V.; Chong, G.; Mourad, G. Arterial hypertension in renal transplant recipients treated with tacrolimus or cyclosporine-Neoral. Transplant. Proc. 2002, 34, 2824–2825. [Google Scholar] [CrossRef]
  27. Campos, H.H.; Abbud, M.F. One-year follow-up of a brazilian randomized multicenter study comparing tacrolimus versus cyclosporine in kidney transplantation. Transplant. Proc. 2002, 34, 1656–1658. [Google Scholar] [CrossRef]
  28. Murphy, G.J.; Waller, J.R.; Sandford, R.S.; Furness, P.N.; Nicholson, M.L. Randomized clinical trial of the effect of microemulsion cyclosporine and tacrolimus on renal allograft fibrosis. Br. J. Surg. 2003, 90, 680–686. [Google Scholar] [CrossRef]
  29. Hardinger, K.L.; Bohl, D.L.; Schnitzler, M.A.; Lockwood, M.; Storch, G.A.; Brennan, D.C. A randomized, prospective, pharcoeconomic trial of tacrolimus versus cyclosporine in combination with thymoglobulin in renal transplant recipients. Transplantation 2005, 80, 41–46. [Google Scholar] [CrossRef]
  30. Silva, H.T., Jr.; Yang, H.C.; Abouljoud, M.; Kuo, P.C.; Wisemandle, K.; Bhattacharya, P.; Dhadda, S.; Holman, J.; Fitzsimmoms, W.; First, M.R. One-year results with extended-release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients. Am. J. Transplant. 2007, 7, 595–608. [Google Scholar] [CrossRef]
  31. Cheung, C.Y.; Chan, H.W.; Liu, Y.L.; Chau, K.F.; Li, C.S. Long-term graft function with tacrolimus and cyclosporine in renal transplantation: Paired kidney analysis. Nephrology 2009, 14, 758–763. [Google Scholar] [CrossRef]
  32. Vicenti, F.; Laskow, D.A.; Neylan, J.F.; Mendez, R.; Matas, A.J. One-year follow-up of an open-label trial of Fk506 for primary kidney transplantation: A report of the U.S. multicenter fk506 kidney transplant group. Transplantation 1996, 61, 1576–1581. [Google Scholar] [CrossRef]
  33. Moreso, F.; Serón, D.; Morales, J.M.; Cruzado, J.M.; Gil-Vernet, S.; Pérez, J.L.; Fulladosa, X.; Andrés, A.; Grinyó, J.M. Incidence of leucopenia and citomegalovirus disease in kidney transplants treated with mycophenolate mofetil combined with low cyclosporine and steroid doses. Clin. Transplant. 1998, 12, 198–205. [Google Scholar]
  34. Raofi, V.; Holman, D.M.; Coady, N.; Vazquez, E.; Dunn, T.B.; Bartholomew, A.M.; Pollak, R.; Benedetti, E. A prospective randomized trial comparing the efficacy of tacrolimus versus cyclosporine in black recipients of primary cadaveric renal transplants. Am. J. Surg. 1999, 177, 299–302. [Google Scholar] [CrossRef]
  35. Sandrini, S.; Maiorca, R.; Scolari, F.; Cancarini, G.; Setti, G.; Gaggia, P.; Cristinelli, L.; Zubani, R.; Bonardelli, S.; Maffeis, R.; et al. A prospective randomized trial on azathioprine addition to cyclosporine versus cyclosporine monotherapy at steroid withdrawal, 6 months after renal transplantation. Transplantation 2000, 69, 1861–1867. [Google Scholar] [CrossRef]
  36. Segoloni, G.; Bonomini, V.; Maresca, M.C.; Arisi, L.; Gonzales-Molina, M.; Tarantino, A.; del Castillo, D.; Ortuño, J.; Carmellini, M.; Capdevila, L.; et al. Tacrolimus is highly effective in bith dual and triple therapy regimens following renal transplantation. Transpl. Int. 2000, 13, S336–S340. [Google Scholar]
  37. Pascual, J.; Segoloni, G.; Gonzales-Molina, G.; del Castillo, D.; Capdevila, L.; Arias, M.; Garcia, J.; Ortuño, J. Comparison between a two-drug regimen with tacrolimus and steroids and a triple one with azathioprine in kidney tansplantation: Results of a European Trial with 3-year follow up. Transplant. Proc. 2003, 35, 1701–1703. [Google Scholar] [CrossRef]
  38. Chang, R.W.S.; Snowden, S.; Palmer, A.; Kwan, J.T.C.; Nocholson, M.; Kashi, S.H.; Fernando, O.N.; Perner, F.; Neild, G.H. European randomized trial of dual versus triple tacrolimus-based regimens for controlof acute rejection in renal allograft recipients. Transpl. Int. 2001, 14, 384–390. [Google Scholar] [CrossRef]
  39. Squifflet, J.P.; Bäckman, L.; Claesson, K.; Dieth, K.H.; Ekberg, H.; Dorsythe, J.L.R.; Kunsendorf, U.; Heemann, U.; Land, W.; Morales, J.M.; et al. Dose Optimization of a Micophenolate Mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients. Transplantation 2001, 72, 63–69. [Google Scholar] [CrossRef]
  40. Hall, B.M.; Tiller, D.J.; Hardie, I.; Mahony, J.; Mathew, T.; Thatcher, G.; Miach, P.; Thomson, N.; Sheil, A.G. Comparison of three immunosuppressive regimens in cadaver renal transplantation: Long-term cyclosporine, short-term cyclosposrine followed by azathioprine and prednisolone, and azathioprine and prednisolone without cyclosporine. N. Engl. J. Med. 1988, 318, 1499–1507. [Google Scholar] [CrossRef]
  41. Schnuelle, P.; van der Heide, J.H.; Tegzess, A.; Verburgh, C.A.; Paul, L.C.; van der Woude, F.J.; de Fijter, J.W. Open randomized trial comparing early withdrawal of either cyclosporine or micophenolate mofetil in stable renal transplant recipients initially treated with a triple drug regimen. J. Am. Soc. Nephrol. 2002, 13, 536–543. [Google Scholar]
  42. Hamdy, A.F.; Bakr, M.A.; Ghoneim, M.A. Long-term efficacy and safety of a calcineurin inhibitor-free regimen in live-donor renal transplant recipients. J. Am. Soc. Nephrol. 2008, 19, 1225–1232. [Google Scholar] [CrossRef]
  43. Groth, C.G.; Bäckman, L.; Morales, J.M.; Kreis, H.; Lang, P.; Touraine, J.L.; Claesson, K.; Campistol, J.M.; Durand, D.; Wramner, L.; et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine. Transplantation 1999, 67, 1036–1042. [Google Scholar] [CrossRef]
  44. Büchler, M.; Caillard, S.; Barbier, S.; Thervet, E.; Toupance, O.; Mazouz, H.; de Ligny, D.H.; Le Meur, Y.; Thierry, A.; Villemain, F.; et al. Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids. Am. J. Transplant. 2007, 7, 2522–2531. [Google Scholar] [CrossRef]
  45. Lebranchu, Y.; Snanoudj, R.; Toupance, O.; Weestel, P.F.; Hurault de Ligny, B.; Buchler, M.; Rerolle, J.P.; Thierry, A.; Moulin, B.; Subra, J.F.; et al. Five-year results of a randomized trial comparing de novo sirolimus and cyclosporine in renal transplantation: The SPIESSER study. Am. J. Transplant. 2012, 12, 1801–1810. [Google Scholar] [CrossRef]
  46. Guba, M.; Pratschke, J.; Hugo, C.; Krämer, B.K.; Nohr-Westphal, C.; Brockman, J.; Andrassy, J.; Reinke, P.; Pressmar, K.; Hakenberg, O.; et al. Renal function, efficacy, and safety of sirolimus ans mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: One-year analysis of a randomized multicenter trial. Tansplantation 2010, 90, 175–183. [Google Scholar]
  47. Glotz, D.; Charpentier, B.; Abramovicz, D.; Lang, P.; Rostaing, L.; Rifle, G.; Vanrenterghem, Y.; Bethous, F.; Bourbigot, B.; Delahousse, M.; et al. Thymoglobulin induction and sirolimus versus tacrolimus in kidney transplant recipients receiving mycophenolate mofetil and steroids. Transplantation 2010, 89, 1511–1517. [Google Scholar] [CrossRef]
  48. Hernández, D.; Miquel, R.; Porrini, E.; Fernández, A.; González-Posada, J.; Hortal, L.; Checa, M.D.; Rodríguez, A.; García, J.J.; Rufino, M.; et al. Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression. Transplantation 2007, 84, 706–714. [Google Scholar] [CrossRef]
  49. Keown, P.; Häyry, P.; Mathew, T.; Morris, P.; Stiller, C.; Barker, C.; Carr, L. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The tricontinental mycophenolate mofetil renal transplantation study group. Transplantation 1996, 61, 1029–1037. [Google Scholar] [CrossRef]
  50. Pescovitz, M.; Conti, D.; Greenstein, S.M.; Inokuchi, S.; Rosenthal, J.; Cohen, D.; Stiller, C.; Pirsch, J.; Tomlanovich, S.; Cho, S.; et al. Mycophenolate Mofetil for The Treatment of a first acute renal allograft rejection. The tricontinental mycophenolate mofetil renal transplantation study group. Transplantation 1998, 65, 235–241. [Google Scholar]
  51. Pescovitz, M.; Conti, D.; Greenstein, S.M.; Inokuchi, S.; Rosenthal, J.; Cohen, D.; Stiller, C.; Pirsch, J.; Tomlanovich, S.; Cho, S.; et al. Mycophenolate mofetil for the treatment of a first acute renal allograft rejection: Three-year follow-up. The mycophenolate mofetil acute renal rejection study group. Transplantation 2001, 71, 1091–1097. [Google Scholar] [CrossRef]
  52. Folkmane, I.; Bicans, J.; Chapenko, S.; Murovska, M.; Rosentals, R. Results of renal transplantation with different immunosuppressive regimens. Transplant. Proc. 2002, 34, 558–559. [Google Scholar] [CrossRef]
  53. Sadek, S.; Medina, J.; Arias, M.; Sennesael, J.; Squifflet, J.P.; Vogt, B. Short-term combination of mycophenolate mofetil with cyclosporine as a therapeutic option for renal transplant recipients. Transplantation 2002, 74, 511–517. [Google Scholar] [CrossRef]
  54. Vítko, S.; Margreiter, R.; Weimar, W.; Dantal, J.; Viljoen, H.G.; Li, Y.; Jappe, A.; Cretin, N. Everolimus (Certican) 12-month safety efficacy versus mycophenolate mofetil in de novo renal transplant recipients. Transplantation 2004, 78, 1532–1540. [Google Scholar] [CrossRef]
  55. Vítko, S.; Margreiter, R.; Weimar, W.; Dantal, J.; Kuypers, D.; Winkler, M.; Oyen, O.; Viljoen, H.G.; Filiptsev, P.; Sadek, S.; et al. Three-year efficacy and safety results form a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am. J. Transplant. 2005, 5, 2521–2530. [Google Scholar] [CrossRef]
  56. Lorber, M.I.; Mulgaonkar, S.; Butt, K.M.H.; Elkhammas, E.; Mendez, R.; Rajagopalan, P.R.; Kahan, B.; Solinger, H.; Li, Y.; Cretin, N.; et al. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: A 3-year randomized, multicenter phase III study. Transplantation 2005, 80, 244–252. [Google Scholar] [CrossRef]
  57. Mendez, R.; Gonwa, T.; Yang, H.C.; Weinstein, S.; Jensik, S.; Steinberg, S. A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: Results at 1 year. Transplantation 2005, 80, 303–309. [Google Scholar] [CrossRef]
  58. Sampaio, E.L.; Pinheiro-Machado, P.G.; Garcia, R.; Felipe, C.R.; Park, S.I.; Casarini, D.E.; Moreira, S.; Franco, M.F.; Tedesco-Silva, H., Jr.; Medina-Pestana, J.O. Mycophenolate mofetil vs. sirolimus in kidney transplant recipients receiving tacrolimus-based immunosuppressive regimen. Clin. Transplant. 2008, 22, 141–149. [Google Scholar]
  59. Tedesco-Silva, H., Jr.; Cibrik, D.; Johnston, T.; Lackova, E.; Mange, K.; Pamos, C.; Walker, R.; Wang, Z.; Zibari, G.; Kim, Y.S. Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard exposure CsA in renal-transplant patients. Am. J. Transplant. 2010, 10, 1401–1413. [Google Scholar] [CrossRef]
  60. Cibrik, D.; Silva, H.T., Jr; Vathsala, A.; Lackova, E.; Cornu-Artis, C.; Walker, RG.; Wang, Z.; Zibari, G.B.; Shihab, F.; Kim, Y.S. Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation. Transplantation 2013, 95, 933–942. [Google Scholar] [CrossRef]
  61. Ekberg, H.; Tedesco-Silva, H.; Demirbas, A.; Vitko, S.; Nashan, B.; Gürkan, A.; Margreiter, R.; Hugo, C.; Grinyó, J.M.; Frei, U.; et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N. Engl. J. Med. 2007, 357, 2562–2575. [Google Scholar] [CrossRef]
  62. Ekberg, H.; Bernasconi, C.; Tedesco-Silva, H.; Vitko, S.; Hugo, C.; Demirbas, A.; Acevedo, R.R.; Grinyó, J.; Frei, U.; Vamrenterghem, Y.; et al. Calcineurin inhibitor minimization in the Symphony Study: Observational results 3 years after transplantation. Am. J. Transplant. 2009, 9, 1876–1885. [Google Scholar] [CrossRef]
  63. Kumar, M.S.A.; Moritz, M.J.; Saaed, M.I.; Heifets, M.; Sustento-Reodica, N.; Fyfe, B.; Kumar, A. Avoidance of chronic steroid therapy in african american kidney transplant recipients monitored by surveilance biopsy: 1-year results. Am. J. Transplant. 2005, 5, 1976–1985. [Google Scholar] [CrossRef]
  64. Tedesco-Silva, H.; Garcia, V.D.; Contieri, F.L.C.; Carvalho, D.B.M.; Noronha, I.L.; Gonçalves, R.T.; de Paula, F.J.; Abbud-Filho, M.; Manfro, R.C.; David-Neto, R. Comparison of the safety and efficacy of cyclosporine minimization versus cyclosporine elimination in de novo renal allograft patients receiving sirolimus. Transplant. Proc. 2010, 42, 1659–1666. [Google Scholar] [CrossRef]
  65. Flechner, S.M.; Glyda, M.; Cockfield, S.; Grinyó, J.; Legendre, C.; Russ, G.; Steinberg, S.; Wissing, K.M.; Tai, S.S. The ORION study: Comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. Am. J. Transplant. 2011, 11, 1633–1644. [Google Scholar] [CrossRef]
  66. Jurewicz, W.A. Tacrolimus versus ciclosporin immunosuppression: Long-term outcome in renal transplantation. Nephrol. Dial. Transplant. 2003, 18, i7–i11. [Google Scholar] [CrossRef]
  67. Fukuhara, N.; Ono, Y.; Hattori, R.; Nishiyama, N.; Yamada, S.; Kamihira, O.; Kinukawa, T.; Ohshima, S. The long-term outcome of tacrolimus in cadaveric kidney transplantation form non-heart beating donors. Clin. Transplant. 2005, 19, 153–157. [Google Scholar] [CrossRef]
  68. Silva, L.A.; Felipe, C.R.; Park, S.I.; Pinheiro-Machado, P.; Garcia, R.; Franco, M.; Moreira, S.R.; Tedesco-Silva, H., Jr.; Medina-Pestana, J. Impact of initial exposure to calcineurin inhibitors on kidney graft function of patients at high risk to develop delayed graft function. Braz. J. Med. Biol. Res. 2006, 39, 43–52. [Google Scholar] [CrossRef]
  69. Gheith, O.A.; Bakr, M.A.; Fouda, M.A.; Shokeir, A.A.; Bayoumy, A.; Sobh, M.; Ghoneim, M. Steroid and azathioprine versus steroid, cyclosporine, and azathioprine therapies in primary haplo-identical living donor kidney transplantation: Twenty-year experience. Iran J. Kidney Dis. 2008, 2, 34–39. [Google Scholar]
  70. Cotovio, P.; Neves, M.; Rodrigues, L.; Alves, R.; Bastos, M.; Baptista, C.; Macário, F.; Mota, A. New-onset diabetes after transplantation: Assessment of risk factors and clinical outcomes. Transplant. Proc. 2013, 45, 1079–1083. [Google Scholar] [CrossRef]
  71. Knight, S.R.; Russell, N.K.; Barcena, L.; Morris, P.J. Mycophenolate mofetil decreases acute rejection and may improve graft survival in renal transplant recipients when compared with azathioprine: A systematic review. Transplantation 2009, 87, 785–794. [Google Scholar] [CrossRef]
  72. Van Hooff, J.P.; Squifflet, J.P. A prospective randomized multicenter study of tacrolimus in combination with sirolimus in renal transplant recipients. Transplantation 2003, 75, 1934–1939. [Google Scholar] [CrossRef]
  73. Webster, A.C.; Lee, V.W.; Chapman, J.R.; Craig, J.C. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: A systematic review and meta-analysis of randomized trials. Transplantation 2006, 81, 1234–1248. [Google Scholar] [CrossRef]
  74. Johnston, O.; Rose, C.L.; Webster, A.C.; Gill, J.S. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J. Am. Soc. Nephrol. 2008, 19, 1411–1418. [Google Scholar] [CrossRef]
  75. Danovitch, G.M. Immunosuppressive Medications and Protocols for Kidney Transplantation. In Handbook of Kidney Transplantation, 4th ed.; Danovitch, G.M., Ed.; Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2005; pp. 72–134. [Google Scholar]
  76. Ribes, D.; Kamar, N. Combined use of tacrolimus and sirolimus in de novo renal transplant patients: Current data. Transplant. Proc. 2005, 37, 2813–2816. [Google Scholar] [CrossRef]
  77. Gralla, J.; Wiseman, A.C. Tacrolimus/sirolimus versus tacrolimus/mycophenolate in kidney transplantation: Improved 3-year graft and patient survival in recent era. Transplantation 2009, 87, 1712–1719. [Google Scholar] [CrossRef]
  78. Yabu, J.M.; Vincenti, F. Kidney Transplantation: The ideal immunosuppression regimen. Adv. Chronic Kidney Dis. 2009, 16, 226–233. [Google Scholar] [CrossRef]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert